Identifying Novel Biomarkers in Early Rheumatology Patients

Study Overview
=================
Brief Summary
-----------------
Patients new to a rheumatology practice will be asked if they want to consent to their blood sample, medical records, and hand/foot x-rays (with sharp scores) for the analysis and correlation with the diagnosis they will receive from the rheumatologist.

Detailed Description
-----------------
At the end of their first visit new rheumatology patients will be asked for their interest in joining the Inova biomarker study. If yes, the patient will be consented, blood will be drawn for the Inova biomarkers, and x-rays will be sent for sharp scoring. Patients may decline and will not be part of the Inova study. Patients who decline will continue to receive standard of care treatment henceforth. Patients in the Inova trial will receive a diagnosis from their doctor and are placed into separate cohorts based upon their diagnosis. The Inova biomarker results of each cohort will be cross-correlated with diagnoses, pre-screening tool results. Baseline disease activity and sharp scores will also be correlation variables.

Official Title
-----------------
Identifying Novel Biomarkers in Early Rheumatology Patients

Conditions
-----------------
Rheumatologic Disorder

Intervention / Treatment
-----------------
* Other: There is no intervention, but a diagnosis.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Newly referred Arthritis Northwest PLLC Age 18 or older Exclusion Criteria: None.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Rheumatoid Arthritis<br>Clinician diagnosed rheumatoid arthritis | Other: There is no intervention, but a diagnosis.<br>* Cohorts will be determined by the primary rheumatology diagnosis.<br>|
| Spondyloarthropathy<br>Ankylosing spondylitis and psoriatic arthritis | Other: There is no intervention, but a diagnosis.<br>* Cohorts will be determined by the primary rheumatology diagnosis.<br>|
| Crystalline arthritis<br>Gout and Pseudo gout | Other: There is no intervention, but a diagnosis.<br>* Cohorts will be determined by the primary rheumatology diagnosis.<br>|
| Connective Tissue Disease<br>Lupus, myositis, scleroderma, and sjogren's | Other: There is no intervention, but a diagnosis.<br>* Cohorts will be determined by the primary rheumatology diagnosis.<br>|
| Non-Inflammatory arthritis<br>E.g. Osteoarthritis and Fibromyalgia | Other: There is no intervention, but a diagnosis.<br>* Cohorts will be determined by the primary rheumatology diagnosis.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The correlation between novel biomarkers and the primary rheumatology diagnosis | Pearson's correlation coefficient of each biomarker to each cohort | 18 month enrollment period. No follow-up period |